New treatment for drug-resistant tuberculosis commences in Papua New Guinea
Evelyn Lavu Travel Scholarship
Burnet welcomes Dr Andrew Nash to its Board of Directors
Providing support to the people of Myanmar
Research Reports + Policy Briefs
IMPACT Magazine
Events
Research Articles
How Science Matters Podcast
Study at Burnet
"Quick, simple, and friendly": Understanding the acceptability and accessibility...
Antimicrobials for Neonates: Practitioner Decisions and Diagnostic Certainty.
Factors Associated with Timely First-Dose Pentavalent and Measles-Rubella Vaccin...
Agency in young people’s unsafe abortion trajectories in Papua New Guinea.
Vaccines
Diagnostics
Therapeutics
Antibody Platforms
Australia
Papua New Guinea
Myanmar
People of Burnet
Leadership
Burnet Partners
Board Members
Appeals
Monthly Giving
Trusts + Foundations
Corporate Supporters
Giving in Wills + Bequests
Supporter Stories
About Us
Careers
History
Annual + Financial Reports
Explore Burnet's progress and journey through this unique series of impact stories.
Burnet maintains a focus on developing and evaluating new interventions to address the most pressing...
Through the years, Burnet’s medical researchers and public health experts have continued to collabor...
Burnet’s innovative and evidence-based public health and laboratory-led COVID-19 research initiative...
Burnet’s experiences in Tibet and parts of China demonstrate a commitment to working with communitie...
Western Province is now making significant progress against TB. Despite ongoing challenges with drug...
In the 1990s, Burnet focused on reducing the risk of harm to PWID by introducing needle exchange pro...
In 2008, Cyclone Nargis hit Myanmar, causing upheaval in the lives of over 2 million people, and kil...
Burnet researchers have led significant discoveries that have proven pivotal in developing next gene...
Burnet now plays a key implementation role, leading an alliance of researchers, public health specia...
